Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
6(55%)
Results Posted
33%(1 trials)

Phase Distribution

Ph phase_1
2
18%
Ph phase_2
6
55%
Ph phase_3
1
9%
Ph not_applicable
1
9%

Phase Distribution

2

Early Stage

6

Mid Stage

1

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
6(60.0%)
Phase 3Large-scale testing
1(10.0%)
N/ANon-phased studies
1(10.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

11

all time

Status Distribution
Active(8)
Completed(3)

Detailed Status

Recruiting5
Completed3
Not yet recruiting2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
6
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (20.0%)
Phase 26 (60.0%)
Phase 31 (10.0%)
N/A1 (10.0%)

Trials by Status

completed327%
not_yet_recruiting218%
active_not_recruiting19%
recruiting545%

Recent Activity

6 active trials
Showing 5 of 11
not_yet_recruitingphase_1

Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma

NCT07835737
completedphase_2

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma

NCT03654833
completedphase_2

Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)

NCT04739202
recruitingphase_2

Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab

NCT07276100
recruitingphase_2

Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)

NCT07293468
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07835737Phase 1

Safety and Efficacy of Folic Acid Combined With Atezolizumab and Bevacizumab as First-Line Therapy for Unresectable Hepatocellular Carcinoma

Not Yet Recruiting
NCT03654833Phase 2

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma

Completed
NCT04739202Phase 2

Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)

Completed
NCT07276100Phase 2

Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab

Recruiting
NCT07293468Phase 2

Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)

Recruiting
NCT04649489Phase 3

A Study to Evaluate Efficacy and Safety of Hepatic Resection for Liver Cancer With PVTT, HVTT or IVCTT After Initial Ate/Bev

Active Not Recruiting
NCT07272265Not Applicable

The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective Study

Completed
NCT07192185Phase 2

Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab

Recruiting
NCT05690048Phase 2

Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)

Recruiting
NCT06971237

SIRT and Peri-immunotherapy : a New Concept

Not Yet Recruiting
NCT06725121Phase 1

Using Radiotherapy and Immunotherapy to Treat Advanced Liver Cancer Before Transplant

Recruiting

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11